



無創性胎兒DNA產前篩檢法

」 敏兒安。 Safe 21

 $\sim \sim$



結合香港中文大學科研 香港首創無創性產前檢查技術

檢測技術

敏兒客**[2]** 是一項高敏性胎兒染色體疾病檢測, 採用現有專利的無創性產前檢測技術,對媽媽和胎兒 的游離DNA進行高通量測序,並將測序結果進行生物 信息分析,從中得知胎兒染色體的遺傳信息。透過 敏兒客fe²了^{express[®]} 可檢測「唐氏綜合症」(T21)、「愛德 華氏綜合症」(T18)、「巴陶氏綜合症」(T13)、性染 色體異數相關資訊及微缺失或微重複症候群。相較於 傳統篩查方法如量度胎兒頸皮或計算媽媽年齡等可靠 及準確,所檢測的項目亦相對較多。



微缺失的原理

微缺失是指染色體上微小的缺失片段,需 要利用較高精細度的檢測儀器去發現, 而 敏兒客 [2] express[€] 所採用的高通量測序技 術,可準確地檢測微小至3Mb的微缺失。



產前檢測比較

敏	记安 21	OSCAR (度頸皮)	染色體核 熒光原 基因	亥型分析/ 位雜交/ Ⅰ晶片
檢測類別	篩查	篩查	診斷性	生測試
抽取樣本	血液🖒	血液 🖒	絨毛球	羊水
檢測孕週	≥10週 心 雙胞胎≥12週	11-14週	11-13週	16-22週
導致流產率	無流產 風險 心	無流產 風險 ♪	0.1-0.2%	0.1-0.2%
報告時間 (工作天)	大約5天	1-2天🖒	7-15天	7-15天
測試項目				
染色體 三體症	\checkmark	\checkmark	\checkmark	\checkmark
性染色體 相關疾病	\checkmark		\checkmark	V
微缺失 症候群	\checkmark		\checkmark	\checkmark



敏兒安fe 21 比傳統早孕 期唐氏綜合症篩查準確度 更高,有助減少30%香港 孕婦因假陽性結果而要進 行入侵性程序如抽絨毛或 抽羊水的機會1.2,降低孕婦 承受額外的流產風險。

-30%

標準版檢測項目

染色體三體症 染色體疾病 T21唐氏綜合症

T18愛德華氏綜

T13巴陶氏綜合

性染色體相關疾病

染色體疾病

X0 X染色體單體 (特納綜合症)

XYY 三體綜合症 (XYY 超雄綜合) 雅各氏綜合症)

XXY 柯林菲特氏

XXX 三體綜合症 (XXX 超雌綜合)

性染色體相關疾病分析準

	準確率	病徵可能包括
	99.65%	先天性心臟/器官缺 陷、聽力/視力問題 及智力障礙。
合症	>99.9%	先天性心臟/大腦/器 官嚴重缺陷及嚴重 智力障礙。嬰兒較 少能存活1年以上。
症	>99.9%	多種先天性嚴重缺陷 及嚴重智力障礙。 嬰兒較少能存活1年 以上。

	病徵可能包括
豊症	心臟缺陷、高血壓、脊椎側 彎、聽力/學習障礙。相對於 同齡女性,患者較多個子矮 小及較遲踏入青春期,而成 年患者較多出現不孕情況。
È 症/	腦癇、哮喘、肌肉張力較弱、 肌肉/語言發展遲緩、學習障 礙、社交困難、情緒失調、 行為問題、自閉症及專注力 不足。相對於同齡,患者身 高高於平均水平。
<i>〔</i> 綜合症	性器官發育不良、肌肉張力 較弱及語言發展遲緩。相對 於同齡,患者身高高於平均 水平,而成年患者較多出現 不孕情況。
È 症)	學習障礙。相對於同齡,患 者身高高於平均水平,而成 年患者較多出現不孕情況。
 離率:99.82	2%

微缺失症候群				
染色體疾病	病徵可能包括			
1p36缺失綜合症	心臟/其他先天性缺陷、肌 肉張力弱、智力障礙及行 為問題。約一半患者會有 腦癎症。			
2q33.1缺失綜合症	生長發育遲緩、嚴重餵養困 難、齶裂及行為問題。			
15q11.2缺失綜合症/ 天使綜合症	生長發育遲緩、腦癎問題、 嚴重智力障礙、語言/平衡/ 行動障礙。			
5p缺失綜合症/ 貓哭綜合症	餵養/呼吸困難、頭小、出 生體重輕及肌肉張力弱、 中度至嚴重智力障礙。			
22q11.2缺失綜合症/ 迪喬治綜合症 [#]	心臟缺陷、免疫系統/腎臟 問題、餵養困難、腦癎症 及輕度至中度智力障礙。			
8q24.1缺失綜合症/ 毛髮-鼻-指骨綜合症	鼻鬆軟呈球莖狀、長的上 唇/人中、頭髮稀疏、骨骼 異常及輕度智力障礙。相 對於同齡,患者較多個子 矮小。			
15q11.2缺失綜合症/ 普瑞德威利綜合症/ 小胖威利綜合症	餵養困難、肌肉張力弱及 智力障礙。部分患者於兒 童及成長期食慾大增,或 有痴肥問題。			
由喬治綜合症分析準確率:94.1%				
^現 竊[2] ^{****} 只能檢測微小至3Mb長 會小於3Mb。由於部分微缺失的函	度的微缺失及微重複,然而上述的微缺失卻有 發生率較低,因此未獲大型數據驗證。			





關於雅士能

雅士能基因科技有限公司自2014年成立,提供獨家授權 專利的全港首創無創性產前檢測服務。此技術源自香港 中文大學創新的科研成果,並獲得世界各地相繼採用。

由創立至今,雅士能藉著不同的基因檢測、先進的實驗 室設備、專業的化驗技術及人員,獲得大眾信任。 未來雅士能將秉持嚴謹、誠懇的態度,專注提供高品 質服務,同時透過基因科技及研發新技術,致力帶動 更多更全面的分析和檢測,繼續守護大眾健康。

關於無創性胎兒DNA 產前篩檢法

敏兒客。21^{express[®]}由香港中文大學團隊研發,採用最新的 基因分析科技以確保高準確率及安全性。與傳統入侵 性測試相比,此技術準確率高及能更早得悉結果,並不 涉及流產風險,從而減低孕婦及其家屬的心理壓力。

現時,雅士能基因科技有限公司是唯一獲得香港中文大 學專利授權於本港進行測試的機構

參考文獻:

1. YM Chan, et al., Prenat. Diagn., 2015; 35(4): 342-347 2. YKY Cheng, et al., BJOG, 2018; 125(4): 451-459

3. A.R. Gregg, et al., Genet, Med., 2016; 18(10); 1056-1065

4. Firth, H.V., et al., DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources, Am.J.Hum.Genet., 2009; 84, 524-533 (DOI:dx.doi.org/10/1016/j.ajhg.2009.03.010)

5. INSERM 1999, (2018). Orphanet: an online rare disease and orphan drug data base Retrieved July 23, 2018, from Orphanet: https://www.orpha.net/consor/cgi-bin/index.phg 6. Johns Hopkins University. (2018). OMIM - Online Mendelian Inheritance in Man.

Retrieved July 23, 2018, from OMIM - Online Mendelian Inheritance in Man: https://www.omim.org/ 7. Wellcome Sanger Institute. (2018, July 18). DECIPHER v9.24. Retrieved July 23, 2018, from DECIPHER v9.24: Mapping the clinical genome: https://decipher.sanger.ac.uk/



雅士能基因科技有限公司 地址:香港新界沙田石門安耀街2號 新都廣場10樓 電話:(852) 3955 1230 傳真:(852) 3565 0112 網址:www.xcelom.com 媽寶學院:www.mabiouni.com









Non-invasive analysis of fetal DNA for prenatal DNA screening

safe 21 person belongs to you and me

ORIGINAL BRAN with Exclusive Patent EADING TECHNOLOGY FROM UNIVERSITY

Non-invasive Prenatal Testing **Pioneered in Hong Kong** Exclusive Patent Licensing from CUHK

The Test and Technology

safe 21 adopts the latest and patented Non-invasive Prenatal Testing Technology (NIPT) for the screening of fetal chromosomal aneuploidies. The test utilizes Next Generation Sequencing followed by bioinformatics analysis on both maternal DNA and cell free placental DNA found in maternal blood. The detection of fetal chromosomal aneuploidies including Down Syndrome (T21), Edwards Syndrome (T18), Patau Syndrome (T13), Sex Chromosome Aneuploidies and microdeletion/microduplication all in ONE test is now made possible. Compared to the traditional screening methods based on nuchal translucency or maternal age, safe 21 stress is more sensitive, reliable, accurate and informative.



Microdeletion Syndrome

Microdeletion syndromes are disorders that are caused by deletion of a small chromosomal segment spanning several genes that is yet too small to be detected by conventional cytogenetic methods. It can only be detected by advanced technology with high resolution. The safe 21 use of Next Generation Sequencing enables the accurate detection of microdeletions with a minimum size of 3Mb.



Prenatal Tests Comparison

	safe 21	OSCAR	Karyot Analy FISH /	/sis /
Test Type	Screening Test	Screening Test	Diagno Tes	
Sample Type	Blood	Blood 🖒	Chorionic Villus	Amniotic Fluid
Gestational Age	≥Week 10 🖒 Twins ≥Week 12	Week 11-14	Week 11-13	Week 16-22
Miscarriage Risk	No 🖒	No🖒	0.1-0.2%	0.1-0.2%
Turnaround Time (Working Days)	About 5 days	1-2 days 🖒	7-15 days	7-15 days
Testing Items				
Trisomies	\checkmark	\checkmark	\checkmark	\checkmark
Sex Chromosome Aneuploidies	~		\checkmark	~
Microdeletions Screening	\checkmark		\checkmark	\checkmark



-30%

Compared to the traditional Down Syndrome screening, safe 21 thas a higher accuracy. This has reduced the need for invasive procedures (performed in Hong Kong) such as Chorionic Villus Sampling (CVS) or Amniocentesis (Amnio) by almost 30%1,2, minimizing the unnecessary risk of miscarriages.

Trisomies

Chromosom Disorders

T21 Down Syndrome

T18 Edwards Svndrome

T13 Patau Syndrome

Chromosoma Disorders

X0 Monosomy X (Turner Syndrome)

XYY Syndrome (Jacob's Syndrome)

XXY Klinefelter Syndrome

XXX Triple X Syndrome

Standard Panel Testing Items

Accuracy	Symptoms may include
99.65%	Birth defects of the heart or other organs. Hearing or vision problems. Intellectual disability.
>99.9%	Severe birth defects of heart, brain and other organs. Severe intellectual disability. Life expectancy of less than 1 year.
>99.9%	Many serious birth defects. Severe intellectual disability. Life expectancy of less than 1 year.

Sex Chromosome Aneuploidies

Symptoms may include
Heart defects. High blood pressure. Scoliosis. Hearing problems. Learning disabilities. Shorter than average in height. Delayed puberty. Infertility.
Epilepsy and Asthma. Hypotonia. Delayed development of motor skills and speech skills. Learning disabilities. Social difficulties. Emotional disorder. Behavioral problem. Autism and insufficient concentration. Taller than average in height.
Impaired development of the sexual

organs. Hypotonia. Delayed speech development. Taller than average in height. Infertility.

Learning disabilities. Taller than average in height. Infertility.

Accuracy of Sex Chromosome Aneuploidies: 99.82%

Microdeletion Syndromes

hromosomal isorders	Symptoms may include		
o36 Deletion yndrome	Heart and other congenital abnormalities. Hypotonia. Intellectual and behavioral problems. Half of them also suffer from epilepsy.		
q33.1 Deletion yndrome	Delayed growth. Significant feeding difficulties. Cleft palate. Behavioral problems.		
5q11.2 Deletion/ ngelman Syndrome	Delayed growth. Epilepsy. Severe intellectual disability and speech impairment. Problems with balancing and movement.		
p Deletion/ ri-du-chat Syndrome	Feeding and breathing difficulties. Smaller head size, low birth weight, and hypotonia in infancy. Moderate to severe intellectual disability.		
2q11.2 Deletion/ iGeorge Syndrome#	Heart, immune system and kidney abnormalities. Feeding difficulties. Epilepsy. Mild to moderate intellectual disability.		
q24.1 Deletion/ anger-Giedion yndrome	Characteristic craniofacial appearance includes a bulbous nose, an elongated upper lip, a long philtrum and sparse hair. Bone abnormalities. Mild intellectual disability. Shorter than average in height.		
5q11.2 Deletion/ rader-Willi Syndrome	Feeding difficulties. Hypotonia. Intellectual disability. Some may develop an insatiable appetite and obesity in childhood.		
uracy of DiGeorge Syndrome: 94.1%			
ce microdeletions are rare, limited data is available for validating the ection rate of most microdeletions. Microdeletions may occur in less than 3MI ze, safe121 ^{mm*} only searches for microdeletions with a minimum size of 3MI			



dete

in siz

Our Services



- Twins/Fetal Reduction:
- ≥12 Weeks
- Triplets: ≥14 Weeks IVF Pregnancy

Non-invasive Procedure

- 10ml Blood
- Fasting is unnecessary No miscarriage risk



All rounded care

- Positive or special cases will be supported by CUHK professors
- Sponsorship for positive cases invasive diagnostic test laboratory test fee



Exclusive Licensee

Exclusive patent from the Chinese University of Hong Kong for the provision of NIPT services in HK



- Singleton: ≥10 Weeks

- (Egg/Sperm Donor)



Report

- Around 5 working days
- Positive / Negative results
- Endorsed by CUHK Obstetrics and Gynaecology medical professionals



Breakthrough Technology

- Next Generation Sequencing
- Combined Count-and Size-Based bioinformatics



Add : 10/F, Metropole Square, 2 On Yiu Street, Shek Mun, Sha Tin, N.T., H.K. Tel : (852) 3955 1230 Fax : (852) 3565 0112 Website : www.xcelom.com MabioUni : www.mabiouni.com











About Xcelom

About Non-invasive Prenatal Testing

safe 21 was invented by a research team from the Chinese University of Hong Kong. It adopts the latest genomics technology, which enables highly accurate and safe prenatal testing. Compared to traditional screening methods, safe 21""" is more sensitive, reliable, accurate and informative, thereby reducing the need for unnecessary invasive procedures, minimizing the emotional stress expecting mothers and their families might have to undergo.

Xcelom Limited is the exclusive licensee of the NIPT patented service from the Chinese University of Hong Kong.

1. YM Chan, et al., Prenat. Diagn., 2015; 35(4): 342-347 2. YKY Cheng, et al., BJOG, 2018; 125(4): 451-459

- 3. A.R. Gregg, et al., Genet. Med., 2016; 18(10): 1056-1065
- 4. Firth, H.V., et al., DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Am.J.Hum.Genet., 2009; 84, 524-533

(DOI:dx.doi.org/10/1016/j.ajhg.2009.03.010 5. INSERM 1999. (2018). Orphanet: an online rare disease and orphan drug data base. Retrieved July 23, 2018, from Orphanet: https://www.orpha.net/consor/cgi-bin/index.ph

6. Johns Hopkins University. (2018). OMIM - Online Mendelian Inheritance in Man. Retrieved July 23, 2018, from OMIM - Online Mendelian Inheritance in Man: https://www.omim.org

7. Wellcome Sanger Institute. (2018, July 18). DECIPHER v9.24. Retrieved July 23, 2018,

from DECIPHER v9.24: Mapping the clinical genome: https://decipher.sanger.ac.uk/

Xcelom Limited



Founded in 2014, Xcelom Limited is the exclusive licensee and provider of Non-invasive Prenatal Testing (NIPT) services in HK. The technology, an innovation by a world-renowned university research team in Hong Kong, has now been adopted worldwide for an